Dikhyaa Mohanty 
The World Health Organization (WHO) informed that it has recommended widespread use of the world’s first Malaria Vaccine known as RTS, S/AS01 (RTS, S) for children in sub-Saharan Africa.
As per WHO officials they informed after a research and development of 30 years by British pharmaceutical company GlaxoSmithKline (GSK) in partnership with the international non-profit organization Program for Appropriate Technology in Health (PATH) and with a network of research centres in Africa, the vaccine for Malaria finally made out.
The WHO further informed that they are recommending after the results from more than 2.3 million doses of the vaccine that have been administered to more than 800,000 children in Ghana, Kenya and Malawi since 2019.
The WHO added that the vaccine has a favourable safety profile and with no negative impact on the uptake of bednets, other childhood vaccinations, or health-seeking behaviour for febrile illness. The vaccine should be provided in a schedule of four doses in children from five months of age for the reduction of malaria disease and burden.
